A coordinated approach for managing polypharmacy among children with medical complexity: rationale and design of the Pediatric Medication Therapy Management (pMTM) randomized controlled trial

Lucas E Orth, Chris Feudtner, Allison Kempe, Megan A Morris, Kathryn L Colborn, R Mark Gritz, Sunny A Linnebur, Anowara Begum, James A Feinstein, Lucas E Orth, Chris Feudtner, Allison Kempe, Megan A Morris, Kathryn L Colborn, R Mark Gritz, Sunny A Linnebur, Anowara Begum, James A Feinstein

Abstract

Background: Children with medical complexity (CMC) often rely upon the use of multiple medications to sustain quality of life and control substantial symptom burden. Pediatric polypharmacy (≥ 5 concurrent medications) is prevalent and increases the risk of medication-related problems (MRPs). Although MRPs are associated with pediatric morbidity and healthcare utilization, polypharmacy is infrequently assessed during routine clinical care for CMC. The aim of this randomized controlled trial is to determine if a structured pharmacist-led Pediatric Medication Therapy Management (pMTM) intervention reduces MRP counts, as well as the secondary outcomes of symptom burden and acute healthcare utilization.

Methods: This is a hybrid type 2 randomized controlled trial assessing the effectiveness of pMTM compared to usual care in a large, patient-centered medical home for CMC. Eligible patients include all children ages 2-18 years old, with ≥ 1 complex chronic condition, and with ≥ 5 active medications, as well as their English-speaking primary caregivers. Child participants and their primary parental caregivers will be randomized to pMTM or usual care before a non-acute primary care visit and followed for 90 days. Using generalized linear models, the overall effectiveness of the intervention will be evaluated using total MRP counts at 90 days following pMTM intervention or usual care visit. Following attrition, a total of 296 CMC will contribute measurements at 90 days, which provides > 90% power to detect a clinically significant 1.0 reduction in total MRPs with an alpha level of 0.05. Secondary outcomes include Parent-Reported Outcomes of Symptoms (PRO-Sx) symptom burden scores and acute healthcare visit counts. Program replication costs will be assessed using time-driven activity-based scoring.

Discussion: This pMTM trial aims to test hypotheses that a patient-centered medication optimization intervention delivered by pediatric pharmacists will result in lower MRP counts, stable or improved symptom burdens, and fewer cumulative acute healthcare encounters at 90 days following pMTM compared to usual care. The results of this trial will be used to quantify medication-related outcomes, safety, and value for a high-utilization group of CMC, and outcomes may elucidate the role of integrated pharmacist services as a key component of outpatient complex care programs for this priority pediatric population.

Trial registration: This trial was prospectively registered at clinicaltrials.gov (NCT05761847) on Feb 25, 2023.

Keywords: Adverse drug events; Children with medical complexity; Deprescribing; Medication safety; Pediatrics; Polypharmacy.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2023. The Author(s).

Figures

Fig. 1
Fig. 1
Study Flow Diagram. Protocolized study flow is depicted. Following enrollment and consent, participants will be randomized 1:1 to pMTM intervention or usual care, with the pMTM intervention occurring ≤ 3 days before a scheduled well child visit or routine follow-up medical encounter. Both groups will then be seen for their scheduled PCP visit as occurring within usual care. Applicable outcomes will be re-assessed at 90-day follow-up
Fig. 2
Fig. 2
Conceptual Framework for pMTM Intervention. This protocol is conceptualized based on the SHED-MEDS model of deprescribing [60]. With permission, we modified this model with the broader core activity of pMTM, during which parents and providers review medication changes, continuation, proper use, monitoring, and follow-up. For children with polypharmacy, our model specifies that the pMTM intervention (which accounts for and prioritizes safety, quality of life, and parental considerations) will lead to patient-centered optimization of medications, resulting in improved health and symptoms manifest as fewer MRPs [4, 12, 30].

References

    1. Feinstein JA, Feudtner C, Valuck RJ, Kempe A. The depth, duration, and degree of outpatient pediatric polypharmacy in Colorado fee-for-service Medicaid patients. Pharmacoepidemiol Drug Saf. 2015;24(10):1049–57. doi: 10.1002/pds.3843.
    1. Feudtner C, Dai D, Hexem KR, Luan X, Metjian TA. Prevalence of polypharmacy exposure among hospitalized children in the United States. Arch Pediatr Adolesc Med. 2012;166(1):9–16. doi: 10.1001/archpediatrics.2011.161.
    1. Feinstein JA, Hall M, Antoon JW, Thomson J, Flores JC, Goodman DM, Cohen E, Azuine R, Agrawal R, Houtrow AJ, DeCourcey DD, Kuo DZ, Coller R, Gaur DS, Berry JG. Chronic Medication Use in Children Insured by Medicaid: A Multistate Retrospective Cohort Study. Pediatrics. 2019;143(4). 10.1542/peds.2018-3397. Epub 2019/03/28. PubMed PMID: 30914443; PMCID: PMC6456893.
    1. Feinstein JA, Friedman H, Orth LE, Feudtner C, Kempe A, Samay S, Blackmer AB. Complexity of Medication Regimens for Children With Neurological Impairment. JAMA Netw Open. 2021;4(8):e2122818. doi: 10.1001/jamanetworkopen.2021.22818.
    1. Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation. BMC Pediatr. 2014;14:199. doi: 10.1186/1471-2431-14-199.
    1. Feinstein JA, Feudtner C, Blackmer AB, Valuck RJ, Fairclough DL, Holstein J, Gregoire L, Samay S, Kempe A. Parent-Reported Symptoms and Medications Used Among Children With Severe Neurological Impairment. JAMA Netw Open. 2020;3(12):e2029082. doi: 10.1001/jamanetworkopen.2020.29082.
    1. Feinstein JA, Feudtner C, Valuck RJ, Fairclough DL, Holstein JA, Samay S, Kempe A. Identifying Important Clinical Symptoms in Children With Severe Neurological Impairment Using Parent-Reported Outcomes of Symptoms. JAMA Pediatr. 2020;174(11):1114–7. doi: 10.1001/jamapediatrics.2020.2987.
    1. Feinstein JA, Rodean J, Hall M, Doupnik SK, Gay JC, Markham JL, Bettenhausen JL, Simmons J, Garrity B, Berry JG. Outpatient Prescription Opioid Use in Pediatric Medicaid Enrollees With Special Health Care Needs. Pediatrics. 2019;143(6). 10.1542/peds.2018-2199. Epub 2019/05/30. PubMed PMID: 31138667; PMCID: PMC6626319.
    1. Blackmer AB, Fox D, Arendt D, Phillips K, Feinstein JA. Perceived Versus Demonstrated Understanding of the Complex Medications of Medically Complex Children. J Pediatr Pharmacol Ther. 2021;26(1):62–72. doi: 10.5863/1551-6776-26.1.62.
    1. Feinstein JA, Morrato EH, Feudtner C. Prioritizing Pediatric Drug Research Using Population-Level Health Data. JAMA Pediatr. 2017;171(1):7–8. doi: 10.1001/jamapediatrics.2016.3462.
    1. Feinstein J, Dai D, Zhong W, Freedman J, Feudtner C. Potential drug-drug interactions in infant, child, and adolescent patients in children's hospitals. Pediatrics. 2015;135(1):e99–108. doi: 10.1542/peds.2014-2015.
    1. Marquez C, Thompson R, Feinstein JA, Orth LE. Identifying opportunities for pediatric medication therapy management in children with medical complexity. Journal of the American Pharmacists Association: JAPhA. 2022. 10.1016/j.japh.2022.04.005. Epub 20220412. PubMed PMID: 35527209.
    1. Feinstein JA, Feudtner C, Kempe A. Adverse drug event-related emergency department visits associated with complex chronic conditions. Pediatrics. 2014;133(6):e1575–85. doi: 10.1542/peds.2013-3060.
    1. Zandieh SO, Goldmann DA, Keohane CA, Yoon C, Bates DW, Kaushal R. Risk factors in preventable adverse drug events in pediatric outpatients. J Pediatr. 2008;152(2):225–31. doi: 10.1016/j.jpeds.2007.09.054.
    1. Walsh KE, Mazor KM, Stille CJ, Torres I, Wagner JL, Moretti J, Chysna K, Stine CD, Usmani GN, Gurwitz JH. Medication errors in the homes of children with chronic conditions. Arch Dis Childhood. 2011;96(6):581–6. doi: 10.1136/adc.2010.204479.
    1. Touchette DR, Stubbings J, Schumock G. Improving Medication Safety in High Risk Medicare Beneficiaries Toolkit. Rockville, MD: Agency for Healthcare Research and Quality; 2012. p. 38.
    1. Lim XY, Yeo QQ, Kng GLL, Chung WL, Yap KZ. Validation of a Drug-Related Problem Classification System for the Intermediate and Long-Term Care Setting in Singapore. Pharmacy (Basel). 2018;6(4). 10.3390/pharmacy6040109. Epub 20181003. PubMed PMID: 30282930; PMCID: PMC6306714.
    1. American Society of Hospital Pharmacists Draft statement on pharmaceutical care ASHP Council on Professional affairs American Society of Hospital Pharmacists. Am J Hosp Pharm. 1993;50(1):126–8.
    1. Willoch K, Blix HS, Pedersen-Bjergaard AM, Eek AK, Reikvam A. Handling drug-related problems in rehabilitation patients: a randomized study. Int J Clin Pharm. 2012;34(2):382–8. doi: 10.1007/s11096-012-9623-5.
    1. Pharmaceutical Care Network Europe. Classification for drug related problems V9.1 2020. Available from: .
    1. Sugioka M, Tachi T, Mizui T, Koyama A, Murayama A, Katsuno H, Matsuyama T, Aoyama S, Osawa T, Noguchi Y, Yasuda M, Goto C, Teramachi H. Effects of the number of drugs used on the prevalence of adverse drug reactions in children. Sci Rep. 2020;10(1):21341. doi: 10.1038/s41598-020-78358-3.
    1. Masica AL, Touchette DR, Dolor RJ, Schumock GT, Kliethermes MA, Rodgers PT, Craft JL, Choi YK, Lux LJ, Smith SR. Evaluation of a Medication Therapy Management Program in Medicare Beneficiaries at High Risk of Adverse Drug Events: Study Methods. In: Henriksen K, Battles JB, Keyes MA, Grady ML, editors. Advances in Patient Safety: New Directions and Alternative Approaches (Vol 4: Technology and Medication Safety). Rockville (MD)2008.
    1. Touchette DR, Masica AL, Dolor RJ, Schumock GT, Choi YK, Kim Y, Smith SR. Safety-focused medication therapy management: a randomized controlled trial. J Am Pharm Assoc (2003). 2012;52(5):603–12. doi: 10.1331/JAPhA.2012.12036.
    1. Woodall T, Landis SE, Galvin SL, Plaut T, Roth McClurg MT. Provision of annual wellness visits with comprehensive medication management by a clinical pharmacist practitioner. Am J Health Syst Pharm. 2017;74(4):218–223. doi: 10.2146/ajhp150938.
    1. Ploenzke C, Kemp T, Naidl T, Marraffa R, Bolduc J. Design and implementation of a targeted approach for pharmacist-mediated medication management at care transitions. J Am Pharm Assoc (2003). 2016;56(3):303–9. doi: 10.1016/j.japh.2016.01.009.
    1. Moczygemba LR, Goode JV, Gatewood SB, Osborn RD, Alexander AJ, Kennedy AK, Stevens LP, Matzke GR. Integration of collaborative medication therapy management in a safety net patient-centered medical home. J Am Pharm Assoc (2003). 2011;51(2):167–72. doi: 10.1331/JAPhA.2011.10191.
    1. Isetts BJ, Schondelmeyer SW, Artz MB, Lenarz LA, Heaton AH, Wadd WB, Brown LM, Cipolle RJ. Clinical and economic outcomes of medication therapy management services: the Minnesota experience. J Am Pharm Assoc (2003). 2008;48(2):203–14. doi: 10.1331/JAPhA.2008.07108.
    1. Smith SM, Wallace E, O'Dowd T, Fortin M. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. Cochrane Database Syst Rev. 2016;3:CD006560. doi: 10.1002/14651858.CD006560.pub3.
    1. Lea M, Mowe M, Mathiesen L, Kvernrod K, Skovlund E, Molden E. Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward. PLoS One. 2019;14(7):e0220071. doi: 10.1371/journal.pone.0220071.
    1. Bogler O, Roth D, Feinstein J, Strzelecki M, Seto W, Cohen E. Choosing medications wisely: Is it time to address paediatric polypharmacy? Paediatr Child Health. 2019;24(5):303–5. doi: 10.1093/pch/pxy188.
    1. Carpenter D, Gonzalez D, Retsch-Bogart G, Sleath B, Wilfond B. Methodological and Ethical Issues in Pediatric Medication Safety Research. Pediatrics. 2017;140(3). 10.1542/peds.2017-0195. Epub 20170804. PubMed PMID: 28778857; PMCID: PMC5574727.
    1. Huth K, Hotz A, Starmer AJ. Patient Safety in Ambulatory Pediatrics. Current Treatment Options in Pediatrics. 2020;6(4):350–365. doi: 10.1007/s40746-020-00213-4.
    1. Huth K, Vandecruys P, Orkin J, Patel H. Medication safety for children with medical complexity. Paediatr Child Health. 2020;25(7):473–4. doi: 10.1093/pch/pxaa105.
    1. El-Rachidi S, LaRochelle JM, Morgan JA. Pharmacists and Pediatric Medication Adherence: Bridging the Gap. Hosp Pharm. 2017;52(2):124–31. doi: 10.1310/hpj5202-124.
    1. Centers for Medicare & Medicaid Services. Medication Therapy Management 2022. Available from: .
    1. Centers for Disease Control and Prevention. Community Pharmacists and Medication Therapy Management Washington, DC2021. Available from: .
    1. Ryan R, Santesso N, Lowe D, Hill S, Grimshaw J, Prictor M, Kaufman C, Cowie G, Taylor M. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. Cochrane Database Syst Rev. 2014;4:CD007768. doi: 10.1002/14651858.CD007768.pub3.
    1. Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, Biggs RS, Cave A, Chang WC, Dzavik V, Farris KB, Galvin D, Semchuk W, Taylor JG. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP) Archives of internal medicine. 2002;162(10):1149–55. doi: 10.1001/archinte.162.10.1149.
    1. American College of Clinical P. McBane SE, Dopp AL, Abe A, Benavides S, Chester EA, Dixon DL, Dunn M, Johnson MD, Nigro SJ, Rothrock-Christian T, Schwartz AH, Thrasher K, Walker S. Collaborative drug therapy management and comprehensive medication management-2015. Pharmacotherapy. 2015;35(4):39–50. doi: 10.1002/phar.1563.
    1. Brummel A, Carlson AM. Comprehensive Medication Management and Medication Adherence for Chronic Conditions. J Manage Care Pharm. 2016;22(1):56–62. doi: 10.18553/jmcp.2016.22.1.56.
    1. Agency for Healthcare Research and Quality. Health Literacy Tools for Providers of Medication Therapy Management 2020. Available from: .
    1. Sneed G, Kappeler K, Gilmore T, Kuhn C. Implementation of a medication therapy management collaborative within a pediatric health system. J Am Pharm Assoc (2003). 2018;58(4S):S114–S9. doi: 10.1016/j.japh.2018.04.021.
    1. You MA, Nam SM, Son YJ. Parental Experiences of Medication Administration to Children at Home and Understanding of Adverse Drug Events. J Nurs Res. 2015;23(3):189–96. doi: 10.1097/jnr.0000000000000080.
    1. The Joint Commission. Preventing pediatric medication errors 2021; 39:[Available from: .
    1. Feinstein JA, Berry JG, Feudtner C. Intervention research to improve care and outcomes for children with medical complexity and their families. Curr Probl Pediatr Adolesc Health Care. 2021;51(12):101126. doi: 10.1016/j.cppeds.2021.101126.
    1. Schenk A, Eckardt-Felmberg R, Steinhagen-Thiessen E, Stegemann S. Patient behaviour in medication management: Findings from a patient usability study that may impact clinical outcomes. Br J Clin Pharmacol. 2020;86(10):1958–68. doi: 10.1111/bcp.13946.
    1. Turner K, Buu J, Kuzel M, Wagoner EV, Berrett GB. Early Implementation of Comprehensive Medication Management within an Academic Medical Center Primary Care Pharmacy Team. Innov Pharm. 2020;11(2). 10.24926/iip.v11i2.3002. Epub 20200430. PubMed PMID: 34007602; PMCID: PMC8051911.
    1. Woeppel J, Clark R, Underwood L, Gatwood J, Turner K, Renfro C, Hohmeier KC. The Tennessee medication therapy management program: A hybrid type 2 effectiveness-implementation trial study protocol. Res Social Adm Pharm. 2020;16(3):315–20. doi: 10.1016/j.sapharm.2019.05.018.
    1. Bradley CL, Luder HR, Beck AF, Bowen R, Heaton PC, Kahn RS, Mansour M, Obszarski S, Frede SM. Pediatric asthma medication therapy management through community pharmacy and primary care collaboration. J Am Pharm Assoc. 2016;56(4):455–60. doi: 10.1016/j.japh.2016.03.007.
    1. McFarland MS, Ourth H, Frank D, Mambourg S, Tran M, Morreale A. Development and validation of a systematic process for expansion of clinical pharmacy activities for comprehensive medication management in primary care within the Department of Veterans Affairs. J Am Coll Clin Pharm. 2021;4(9):1126–1133. doi: 10.1002/jac5.1449.
    1. Benavides S, Madzhidova S, Hernandez A, Le T, Palma SM, Stephen S. Establishment of Pediatric Medication Therapy Management: A Proposed Model. Pharmacy (Basel). 2016;4(1). 10.3390/pharmacy4010005. Epub 20160119. PubMed PMID: 28970378; PMCID: PMC5419360.
    1. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322–7. doi: 10.2105/ajph.89.9.1322.
    1. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–207. doi: 10.7326/0003-4819-158-3-201302050-00583.
    1. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi: 10.1136/bmj.e7586.
    1. Schulz KF, Altman DG, Moher D, Group C CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18. doi: 10.1186/1741-7015-8-18.
    1. Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P, Group CN CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40–7. doi: 10.7326/M17-0046.
    1. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–57. doi: 10.1093/intqhc/mzm042.
    1. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Medical care. 2012;50(3):217–26. doi: 10.1097/MLR.0b013e3182408812.
    1. Abdellatif A, Bagian JP, Barajas ER, Cohen M, Cousins D, Denham CR, Essinger K, Gegelashvili G, Glenister H, Hoffman C, Horvath D, Khoja T, Klazinga N, Lee CE, Letlape TK, Lilja B, Manasse HR, Massoud MR, Wilson RM, Medici AC, Mohammad AJ, Munier WB, Murphy M, Murphy ML, Ortiz Z, Pinakiewicz DC, Pittet D, Reznikovich S, Rudolph B, Sheridan SE, Siu-fai L, Solomon RP, Svensson PG, Whittaker S, Youngson R. Assuring Medication Accuracy at Transitions in Care. Joint Commission J Qual Patient Safety. 2007;33(7):450–453. doi: 10.1016/s1553-7250(07)33131-0.
    1. Vasilevskis EE, Shah AS, Hollingsworth EK, Shotwell MS, Mixon AS, Bell SP, Kripalani S, Schnelle JF, Simmons SF, Shed MT. A patient-centered deprescribing intervention for hospitalized older patients with polypharmacy: rationale and design of the Shed-MEDS randomized controlled trial. BMC Health Serv Res. 2019;19(1):165. doi: 10.1186/s12913-019-3995-3.
    1. Marquez C, Thompson R, Feinstein JA, Orth LE. Identifying opportunities for pediatric medication therapy management in children with medical complexity. J Am Pharm Assoc. 2022. 10.1016/j.japh.2022.04.005. Epub 20220412. PubMed PMID: 35527209.
    1. Services. CfMM. Medicare Part D medication therapy management program standarized format 2013. Available from: .
    1. Lee SY, Stucky BD, Lee JY, Rozier RG, Bender DE. Short Assessment of Health Literacy-Spanish and English: a comparable test of health literacy for Spanish and English speakers. Health Serv Res. 2010;45(4):1105–20. doi: 10.1111/j.1475-6773.2010.01119.x.
    1. Kripalani S, Henderson LE, Chiu EY, Robertson R, Kolm P, Jacobson TA. Predictors of medication self-management skill in a low-literacy population. J Gen Intern Med. 2006;21(8):852–6. doi: 10.1111/j.1525-1497.2006.00536.x.
    1. Bell SP, Schnipper JL, Goggins K, Bian A, Shintani A, Roumie CL, Dalal AK, Jacobson TA, Rask KJ, Vaccarino V, Gandhi TK, Labonville SA, Johnson D, Neal EB, Kripalani S. Pharmacist Intervention for Low Literacy in Cardiovascular Disease Study G. Effect of Pharmacist Counseling Intervention on Health Care Utilization Following Hospital Discharge: A Randomized Control Trial. J Gen Intern Med. 2016;31(5):470–7. doi: 10.1007/s11606-016-3596-3.
    1. Erickson SR, LeRoy B. Health literacy and medication administration performance by caregivers of adults with developmental disabilities. J Am Pharm Assoc. 2015;55(2):169–77. doi: 10.1331/JAPhA.2015.14101.
    1. Yin HS, Dreyer BP, Foltin G, van Schaick L, Mendelsohn AL. Association of low caregiver health literacy with reported use of nonstandardized dosing instruments and lack of knowledge of weight-based dosing. Ambul Pediatr. 2007;7(4):292–8. doi: 10.1016/j.ambp.2007.04.004.
    1. Yin HS, Mendelsohn AL, Wolf MS, Parker RM, Fierman A, van Schaick L, Bazan IS, Kline MD, Dreyer BP. Parents' medication administration errors: role of dosing instruments and health literacy. Arch Pediatr Adolesc Med. 2010;164(2):181–6. doi: 10.1001/archpediatrics.2009.269.
    1. Yin HS, Parker RM, Sanders LM, Mendelsohn A, Dreyer BP, Bailey SC, Patel DA, Jimenez JJ, Kim KA, Jacobson K, Smith MCJ, Hedlund L, Meyers N, McFadden T, Wolf MS. Pictograms, Units and Dosing Tools, and Parent Medication Errors: A Randomized Study. Pediatrics. 2017;140(1). 10.1542/peds.2016-3237. Epub 2017/08/02. PubMed PMID: 28759396; PMCID: PMC5495522.
    1. Dahmash DT, Shariff ZB, Kirby DJ, Terry D, Huynh C. Literature review of medication administration problems in paediatrics by parent/caregiver and the role of health literacy. BMJ Paediatr Open. 2020;4(1):e000841. doi: 10.1136/bmjpo-2020-000841.
    1. Bazaldua OV, Davidson DA, Zurek A, Kripalani S. Health Literacy and Medication Use. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: A Pathophysiologic Approach, 10e. New York, NY: McGraw-Hill Education; 2017.
    1. Kripalani S, Jacobson TA, Mugalla IC, Cawthon CR, Niesner KJ, Vaccarino V. Health literacy and the quality of physician-patient communication during hospitalization. J Hosp Med. 2010;5(5):269–75. doi: 10.1002/jhm.667.
    1. Boyle J, Speroff T, Worley K, Cao A, Goggins K, Dittus RS, Kripalani S. Low Health Literacy Is Associated with Increased Transitional Care Needs in Hospitalized Patients. J Hosp Med. 2017;12(11):918–24. doi: 10.12788/jhm.2841.
    1. Reeve E, Low LF, Shakib S, Hilmer SN. Development and Validation of the Revised Patients' Attitudes Towards Deprescribing (rPATD) Questionnaire: Versions for Older Adults and Caregivers. Drugs Aging. 2016;33(12):913–28. doi: 10.1007/s40266-016-0410-1.
    1. National Quality Forum. Composite Performance Measure Evaluation Washington, DC: National Quality Forum; 2013. Available from: .
    1. Centers for Medicare & Medicaid Services. Composite Measures for Accountability Programs 2022. Available from: .
    1. Barclay M, Dixon-Woods M, Lyratzopoulos G. The problem with composite indicators. BMJ Qual Saf. 2019;28(4):338–44. doi: 10.1136/bmjqs-2018-007798.
    1. Feinstein JA, Feudtner C, Kempe A, Orth LE. Anticholinergic Medications and Parent-Reported Anticholinergic Symptoms in Neurologically Impaired Children. J Pain Symptom Manage. 2023;65(2):e109–e14. doi: 10.1016/j.jpainsymman.2022.10.013.
    1. George J, Phun YT, Bailey MJ, Kong DC, Stewart K. Development and validation of the medication regimen complexity index. Ann Pharmacother. 2004;38(9):1369–76. doi: 10.1345/aph.1D479.
    1. Hirsch JD, Metz KR, Hosokawa PW, Libby AM. Validation of a patient-level medication regimen complexity index as a possible tool to identify patients for medication therapy management intervention. Pharmacotherapy. 2014;34(8):826–35. doi: 10.1002/phar.1452.
    1. Schoonover H, Corbett CF, Weeks DL, Willson MN, Setter SM. Predicting potential postdischarge adverse drug events and 30-day unplanned hospital readmissions from medication regimen complexity. J Patient Safety. 2014;10(4):186–91. doi: 10.1097/PTS.0000000000000067.
    1. Tjugum SL, Hansen BK, McKinzie CJ. Association of Medication Regimen Complexity With Clinical Endpoints in Pediatric Patients With Cystic Fibrosis. J Pediatr Pharmacol Ther. 2021;26(3):248–52. doi: 10.5863/1551-6776-26.3.248.
    1. Pendergrass A, Malnis C, Graf U, Engel S, Graessel E. Screening for caregivers at risk: Extended validation of the short version of the Burden Scale for Family Caregivers (BSFC-s) with a valid classification system for caregivers caring for an older person at home. BMC Health Serv Res. 2018;18(1):229. doi: 10.1186/s12913-018-3047-4.
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–D82. doi: 10.1093/nar/gkx1037.
    1. Institute for Safe Medication Practices. High-Alert Medications in Community/Ambulatory Settings. Available from: .
    1. Kripalani S, Risser J, Gatti ME, Jacobson TA. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value Health. 2009;12(1):118–23. doi: 10.1111/j.1524-4733.2008.00400.x.
    1. Creswell JW, Poth CN. Qualitative inquiry & research design : choosing among five approaches. 4. Los Angeles: SAGE; 2018. p. xxv, 459.
    1. Cidav Z, Mandell D, Pyne J, Beidas R, Curran G, Marcus S. A pragmatic method for costing implementation strategies using time-driven activity-based costing. Implement Sci. 2020;15(1):28. doi: 10.1186/s13012-020-00993-1.
    1. U.S. Bureau of Labor and Statistics. Overview of BLS Statistics on Pay and Benefits Washington, DC: United States Department of Labor; 2022. Available from: .
    1. Chapel JM, Wang G. Understanding cost data collection tools to improve economic evaluations of health interventions. Stroke Vasc Neurol. 2019;4(4):214–22. doi: 10.1136/svn-2019-000301.
    1. Eisman AB, Kilbourne AM, Dopp AR, Saldana L, Eisenberg D. Economic evaluation in implementation science: Making the business case for implementation strategies. Psychiatry Res. 2020;283:112433. doi: 10.1016/j.psychres.2019.06.008.
    1. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277–88. doi: 10.1177/1049732305276687.
    1. Antoon JW, Hall M, Herndon A, Carroll A, Ngo ML, Freundlich KL, Stassun JC, Frost P, Johnson DP, Chokshi SB, Brown CM, Browning WL, Feinstein JA, Grijalva CG, Williams DJ. Prevalence of Clinically Significant Drug-Drug Interactions Across US Children's Hospitals. Pediatrics. 2020;146(5). 10.1542/peds.2020-0858. Epub 20201009. PubMed PMID: 33037121; PMCID: PMC7786820.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj